drugset
drugset / Trial / NCT00492921

High-Dose Cyclophosphamide for Steroid Refractory GVHD

NCT00492921 ↗

Phase 2 Completed 12 enrolled Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins National Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelSupportive care

Summary

RATIONALE: High-dose cyclophosphamide may be an effective treatment for acute graft-versus-host disease that did not respond to steroid therapy. PURPOSE: This phase II trial is studying the side effects, best dose, and how well high-dose cyclophosphamide works in treating patients with acute graft-versus-host disease that did not respond to steroid therapy.

Timeline

Start
2007-05
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 50 mg/kg —

Indications

acute graft versus host disease